B.Riley Financial Sticks to Its Buy Rating for Mustang Bio (MBIO)


B.Riley Financial analyst Justin Zelin reiterated a Buy rating on Mustang Bio (MBIO) today and set a price target of $13.00. The company’s shares closed last Monday at $3.18.

According to TipRanks.com, Zelin is a 3-star analyst with an average return of 8.3% and a 61.5% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Abeona Therapeutics, Krystal Biotech, and Heat Biologics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mustang Bio with a $11.00 average price target, implying a 186.5% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

See today’s analyst top recommended stocks >>

Based on Mustang Bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.95 million. In comparison, last year the company had a GAAP net loss of $10.17 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm’s products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts